NEW YORK: Researchers have announced their findings from a new study entitled, ‘PSEN1 Variant in a Family with Atypical AD,’ in which an Alzheimer patient with very severe disease, genetically confirmed to have a known variant of PSEN1, showed promising benefits during treatment with the drug Bryostatin 1.
Genetically confirmed Alzheimer’s patients as severely advanced as patient IV-18 have not shown this level of clinical improvement previously with other treatment(s)…